Enter content here

Enter content here

 
HomeDevelopment of recombinant p21 protein as a viable therapy for AIDSINVESTORS NEEDEDSCIENCE CONSULTANTNEWSExecutive SummaryBreast Cancer testp21 drug development

CONTACT US

INVESTORS NEEDED

OPPORTUNITY FOR INVESTORS

AN EXCELLENT OPPORTUNITY FOR VENTURE CAPITALISTS AND ANGEL INVESTORS TO INVEST IN A START UP BIOTECH COMPANY
INTERESTED IN MILE STONE DRIVEN DEVELOPMENT OF RECOMBINANT PROTEIN BASED THERAPEUTIC AGENT FOR:
  • ORGAN TRANSPLANT REJECTION
  • INDUCTION OF IMMUNE TOLERANCE
  • ATHEROSCLEROSIS
  • ARTHRITIS

DEVELOPMENT OF MOLECULAR DIAGNOSTIC ASSAY FOR BREAST CANCER 

Enter supporting content here